*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
You are seeing these quotes based on previous browsing related to sectors such as
Glaxosmithkline Plc (GSK)
$33.60
11:10 20/12/24
0.51%$0.17
Today's Low & High
33.04 / 33.87
Open / Previous Close
33.13 / 33.60
52-week range
-7.16%-$2.59
Volume
6,808,123
Market Cap(million)
$15,648.12m
Advertising
Glaxosmithkline Plc - Overview
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
Registrars:
Key Personnel
CEO:
Emma Walmsley
Non-Executive Director:
Hal Barron , Wendy Becker , Jeannie Lee
Non-Executive Chairman:
Jonathan Symonds
Senior Independent Non-Executive Director:
Charles Bancroft
Chief Finance Officer:
Julie Brown
Independent Non-Executive Director:
Jesse Goodman, Elizabeth (Liz) McKee Anderson, Anne Beal, Harry (Hal) C. Dietz, Vishal Sikka